Targeted therapy may delay end-of-life transition, study finds

12/6/2012 | MedWire News (U.K.)

Targeted therapies such as bevacizumab, erlotinib, sorafenib and rituximab are increasingly are used in advanced cancer patients at the end of life, according to research from the University of Texas MD Anderson Cancer Center. The study team wrote in the Journal of Pain and Symptom Management these treatments are used about as often as chemotherapy and could delay a transition in care, "diverting patients' precious time and energy to the pursuit of cancer treatments rather than planning ahead."

View Full Article in:

MedWire News (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD